Drug class
Chimeric anti-GD2 monoclonal IgG1 antibody; antineoplastic immunotherapy
Mechanism of action
Binds the GD2 disialoganglioside expressed on neuroblastoma cells and triggers complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to tumour-cell lysis.
General use cases
- Treatment of high-risk neuroblastoma in patients aged 12 months and older who previously received induction chemotherapy and achieved at least a partial response, as part of post-consolidation therapy; use with required combination agents and product-specific conditions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
